Hims & Hers

Hims & Hers

Hims & Hers is a direct-to-consumer telehealth and pharmaceutical company specializing in accessible, discreet care for chronic conditions and wellness needs. Founded in 2017, the company leverages a digital platform to connect patients with licensed healthcare professionals for online consultations and prescription fulfillment. It has grown rapidly by focusing on stigmatized or underserved areas of health, such as sexual health, dermatology, and mental health, primarily targeting millennial and Generation Z consumers. The company is publicly traded on the New York Stock Exchange under the ticker symbol "HIMS".

History

The company was co-founded in San Francisco, California by Andrew Dudum and Jack Abraham, with Dudum serving as Chief Executive Officer. The concept emerged from identifying a market gap for convenient, judgment-free access to treatments for common conditions like erectile dysfunction and hair loss. In its early years, the company gained significant traction through targeted social media marketing and a streamlined user experience. A major milestone was its 2021 merger with the special purpose acquisition company Oaktree Acquisition Corp., which took it public in a deal valued at approximately $1.6 billion. This move provided capital for significant expansion into new therapeutic areas and the scaling of its platform.

Business model

The core business model operates on a subscription business model for ongoing treatments and a per-consultation fee for one-time services. Revenue is generated through monthly or quarterly subscription plans for medications and personalized care kits, which include both prescription and over-the-counter drug products. The company maintains a network of independent, licensed physicians and nurse practitioners across the United States to conduct virtual visits and prescribe medications where appropriate. This asset-light approach allows for scalability without the overhead of physical clinics, while partnerships with pharmacy benefit managers and fulfillment centers handle logistics. The model emphasizes recurring revenue and high customer lifetime value through retention in chronic care categories.

Products and services

The company's offerings are segmented by brand, with "Hims" targeting men and "Hers" targeting women. Key product categories include sexual health, featuring treatments for erectile dysfunction (e.g., sildenafil, tadalafil) and herpes simplex virus; dermatology, with prescriptions for acne, anti-aging creams, and hair loss treatments like finasteride and minoxidil; and mental health, providing access to selective serotonin reuptake inhibitors for depression and generalized anxiety disorder. The platform also offers primary care services for areas like weight management, asthma, and cholesterol, alongside a range of vitamins and skincare products. All treatments are preceded by an online medical consultation to ensure appropriateness and safety.

Financial performance

Following its public debut, the company has demonstrated rapid revenue growth, consistently reporting increasing quarterly and annual gross merchandise value and total revenue. Key financial metrics reported to the Securities and Exchange Commission show a path toward profitability, with significant investment in sales and marketing to acquire new customers. The company's financial strategy involves balancing customer acquisition costs with the long-term value of subscriptions, and it has periodically raised additional capital through equity financing. Its performance is closely watched by analysts as a bellwether for the broader digital health and telemedicine sector, with comparisons often made to competitors like Teladoc Health and Ro.

Legal and regulatory issues

Operating in the highly regulated healthcare industry, the company navigates complex frameworks including the Food and Drug Administration's rules on drug approval and marketing, and state-by-state regulations governing the practice of medicine and telehealth. It has faced scrutiny and legal challenges regarding its prescribing practices, with some critics alleging overly permissive consultations. The company must also ensure strict compliance with the Health Insurance Portability and Accountability Act for patient data privacy and security. Furthermore, its advertising, particularly on platforms like Instagram and Facebook, is subject to oversight by the Federal Trade Commission regarding substantiated health claims.